Athenese-Dx Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-11-2024
- Paid Up Capital ₹ 7.02 M
as on 16-11-2024
- Company Age 12 Year, 9 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 5.00 M
as on 16-11-2024
- Revenue -9.63%
(FY 2023)
- Profit -63.84%
(FY 2023)
- Ebitda -39.33%
(FY 2023)
- Net Worth 16.96%
(FY 2023)
- Total Assets 15.08%
(FY 2023)
About Athenese-Dx
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 7.02 M.
The company has closed loans amounting to ₹5.00 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Catherine Chen, Arunkumar Chakravarthy, and Selvaraju Govindasamy serve as directors at the Company.
- CIN/LLPIN
U85100TN2012PTC084632
- Company No.
084632
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 Feb 2012
- Date of AGM
21 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Athenese-Dx Private Limited offer?
Athenese-Dx Private Limited offers a wide range of products and services, including Medical Laboratory Instruments, PCR Machine, Corona Test Kit, Rapid Test Kit, Typhoid Test Kit, Elisa Kits, Pathology Lab Equipments, Elisa Reader.
Who are the key members and board of directors at Athenese-Dx?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Catherine Chen  | Director | 17-Feb-2016 | Current |
Arunkumar Chakravarthy  | Whole-Time Director | 06-Jan-2017 | Current |
| Selvaraju Govindasamy | Director | 17-Jul-2020 | Current |
Financial Performance and Corporate Structure Insights of Athenese-Dx.
Athenese-Dx Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 9.63% decrease. The company also saw a substantial fall in profitability, with a 63.84% decrease in profit. The company's net worth Soared by an impressive increase of 16.96%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Athenese-Dx?
In 2023, Athenese-Dx had a promoter holding of 75.97% and a public holding of 24.03%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 28 May 2020 | ₹5.00 M | Satisfied |
How Many Employees Work at Athenese-Dx?
Athenese-Dx has a workforce of 289 employees as of May 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Athenese-Dx, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Athenese-Dx's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
